Several diagnostic panels based on a combination of liver tests and clinical parameters such as the NAFLD fibrosis score (age, body mass index (BMI), diabetes status, with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, platelet count and albumin) and FIB-4 score (age, BMI, AST/ALT ratio and platelet count) have been developed to facilitate the non-invasive assessment of NAFLD severity [9]. The gene discussed is GPT; the disease is fibrosis.